
Taurine Might Not Be the Anti-Aging Miracle We Hoped For
New research hasn't found any connection between taurine levels in the blood and our age.
You might want to hold off on stockpiling taurine supplements as part of your anti-aging cocktail. Research published today failed to find evidence that our levels of taurine shrink as we get older, contrary to some earlier studies.
Scientists at the National Institutes of Health led the research, published Thursday in Science. They analyzed long-running data from past human, mice, and monkey studies, finding that taurine levels didn't change much over time and widely varied between individual animals. The results suggest that taurine isn't a good marker for age and throw into doubt the idea that it can prolong healthy aging.
'Circulating taurine doesn't decline with age in healthy individuals of these three mammalian species across the adult lifespan,' said lead study researcher Maria Emilia Fernandez, a postdoctoral fellow in the Translational Gerontology Branch of the NIH's National Institute on Aging, in a press conference Tuesday announcing the findings.
Taurine is a semi-essential and important micronutrient. Our bodies naturally produce taurine, though it can also easily be found in animal products, supplements, and energy drinks (people once collected taurine from bulls, but it's now produced synthetically). Taurine plays many roles in the body, such as helping us make bile acid and keeping our blood pressure stable. In recent years, some studies have indicated that taurine—or rather, the loss of taurine—might also be a key driver of our worsening health as we get older.
A 2023 study that looked at several different animal models, for instance, found that taurine levels circulating in the blood appeared to decline as the animals aged. When the researchers added taurine supplements to the animals' diets, it appeared to slightly extend the lifespan of mice and worms in addition to improving the health of older monkeys. The study also found an association between lower taurine levels in humans and an increased risk of age-related diseases.
Though this wasn't the first research to suggest taurine's anti-aging potential, it certainly sparked people's attention, including the authors behind this latest research. Not every bit of research on the topic has supported this link, however, and many studies have only analyzed taurine in people and animals at a single point in time or for a relatively brief period. The researchers behind the new study wanted to take a closer look at how these levels fluctuated over time across different species and in both males and females.
They turned to other existing studies or projects involving people, mice, and rhesus monkeys that had longitudinal data on taurine levels in the blood—meaning they could track these levels across the lifespan. Overall, they found that taurine levels didn't decline in any of the animals or humans they studied; if anything, taurine levels usually increased over time in different groups (the sole exception being male mice). They also found that differences in taurine levels between individuals could sometimes vary significantly, and that these differences were usually larger than the changes seen over an animal's lifetime.
In other words, there doesn't appear to be much of a connection at all between taurine and aging, at least in this research. 'On the basis of these findings, we conclude that low circulating taurine concentrations are unlikely to serve as a good biomarker of aging,' the researchers wrote.
These are still findings from a single study, so more research will be needed to settle the question. The results also don't mean that taurine isn't important to our health. And it is still possible that low taurine levels can contribute to chronic health problems, including conditions that become more common as we age. Likewise, there may be some older people with low taurine who would benefit from increasing their intake.
Vijay Yadav, one of the authors behind the 2023 study, and his colleagues are currently running a randomized clinical trial testing whether taurine supplements can improve the health and fitness of middle-aged adults. He expects the trial to conclude by the end of 2025, with analysis coming soon after. For now, though, Yadav isn't saying that people should be downing taurine like it's candy.
'We cannot really recommend any supplementation. We need to have a better understanding if it does or it does not [improve health]; that can only be addressed by a placebo controlled trial,' said Yadav in the same press conference Tuesday. 'And of course there are a lot more questions that need to be addressed before you can really understand the biology to more depth of a particular molecule.'
While there are certainly things people can already do to stay healthier into their golden years, such as exercising regularly, the track record for anti-aging drugs or supplements overall remains spotty for the time being. And it seems that a universal fountain of youth—if we can ever truly find it—probably won't contain any taurine.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
33 minutes ago
- CBS News
A woman's heart suddenly stopped. Two passing nurses saved her life.
Merryl Hoffman knew she was taking good care of her heart. The 63-year-old attorney didn't smoke or drink, and she was an avid hiker who used to run marathons and other distance races. In her 40s, she had been diagnosed with a leaky mitral valve and underwent surgery to repair it. Every year since, she has seen a cardiologist to check her heart and its function. The reports always came back clear. When Hoffman left her apartment on Manhattan's Upper East Side on Oct. 23, 2025, her heart was the last thing on her mind. She was saddled with her work bag and purse, hightailing it to the subway station so she could make it to work on time. That's when her memory of the day ends. Shortly into her walk, Hoffman experienced a sudden cardiac arrest. Her heart stopped beating. She collapsed to the ground. Doctors later told her it was a severe arrhythmia that could have been fatal — if not for where Hoffman fell. Hoffman had collapsed outside Memorial Sloan Kettering Cancer Center's Breast and Imaging Center, about two and a half blocks from her subway station. A patient care technician and a passing runner immediately rushed to her aid. Then, Memorial Sloan Kettering nurses Sabrina Castle and Gianna Formisano stumbled upon the scene while walking to work. "We were so shocked. When we were walking up, people were like 'Nurses, nurses!' We didn't know what we were walking into," Formisano said. "People were grabbing our coffee, taking our bags. It was out of a movie, the way that they were like 'Oh, thank God you're here.'" Sabrina Castle and Gianna Formisano outside the Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering "They absolutely saved my life" Formisano and Castle took over performing CPR, keeping Hoffman's heart manually beating. She didn't have a pulse, and she had hit her head when she collapsed. The nurses also instructed one of the other bystanders to call an ambulance. Early CPR increases survival for patients in cardiac arrest by "at least two or three fold," said Dr. Jessica Hennessey, a cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center. Early CPR means that blood flow to the brain and heart continues, preserving the health of those organs. Bystanders in a medical emergency should call 911 and immediately start CPR, Hennessey advised. CPR can be done with mouth-to-mouth or with just chest compressions, Hennessey said. After five minutes that "felt like forever," the ambulance arrived, Formisano said. Castle and Formisano helped the EMTs load Hoffman into the ambulance. Then, she was taken to NewYork-Presbyterian's cardiac care unit for further treatment. For the small crowd, the day carried on. Castle and Formisano headed to work. After a few hours, they called NewYork-Presbyterian to see if they could find out more about Hoffman's status. They went to the hospital and spoke to a nurse there. "She was like, 'You got her back. She's intubated, she's alive, you saved her life,'" Castle recalled. Hoffman was still unconscious. She told CBS News that she didn't wake up until five days after the collapse. Her family told her that she had been rushed into surgery. Doctors told her that her heart had stopped for several minutes -- and the actions of Castle, Formisano and other bystanders had saved her. "Without them, I was told, there was no doubt I would have died or been brain dead," Hoffman said. "They absolutely saved my life." Hoffman had an implantable cardioverter-defibrillator placed in her chest to prevent further cardiac arrests. The device shocks the heart if it detects an irregular heartbeat. She also began cardiac rehabilitation. Shortly after, she returned to work. Life began to get back to normal but one question was constantly at the back of her mind: Who had helped save her? A chance reunion While in cardiac rehabilitation, Hoffman found herself telling the story of the strangers who had helped her. A physiologist there overheard her talking about it and thought the story sounded familiar. His girlfriend was friends with two nurses who had helped a woman matching Hoffman's description. After some back and forth, the physiologist connected Hoffman with Castle and Formisano. The trio immediately made plans to get dinner. Hoffman's husband joined them for the meal. There, the nurses were able to fill in the gaps of the October morning when Hoffman collapsed. Sabrina Castle, Merryl Hoffman and Gianna Formisano at the site where Hoffman collapsed. Sabrina Castle and Gianna Formisano "It was very jarring, when they gave my husband and I the blow-by-blow of that morning. There were things we did not know," Hoffman said. "It was pretty incredible." Since that dinner, the women have stayed in touch. Recently, Castle and Formisano even passed Hoffman on the same block where she had collapsed. The three took a photo at the site. "We were like, 'Wow, this is really crazy,'" Formisano said. "'We're running into you on the same spot, on your way to work, on our way to work, but now you're alive and well and in a much different state than when we met you the first time.'"
Yahoo
33 minutes ago
- Yahoo
Federal cuts force families to make difficult, and potentially deadly, choices
A mother rushes into the emergency department cradling her 6-month-old baby. He is lethargic, seizing and in critical condition. The cause? Severely low sodium levels in his blood — a result of formula diluted with extra water to make it last longer. With grocery prices climbing and her SNAP benefits running out before the end of the month, she felt she had no other choice. This story is not an outlier. Pediatric clinicians across Wisconsin are seeing the real and devastating consequences of policies that fail to prioritize the health and well-being of children and families. And now, the situation could get worse. The Trump Administration's proposed 'skinny' budget for Fiscal Year 2026 includes deep and dangerous cuts to federal programs that form the backbone of public health in our communities. These proposed reductions include: $18 billion from the National Institutes of Health – stalling critical pediatric research and innovation $3.5 billion from the Centers for Disease Control and Prevention – compromising disease surveillance, immunization programs, and emergency response efforts $1.73 billion from the Health Resources and Services Administration – cutting access to essential primary and preventive care services for children and families $674 million from the Centers for Medicare & Medicaid Services – threatening the Medicaid and CHIP programs that provide health coverage to nearly half of Wisconsin's children. Opinion: We asked readers about wake boats on Wisconsin lakes. Here's what you said. And as if that weren't enough, further reductions to SNAP and other nutrition support programs are also on the table. These aren't just numbers on a spreadsheet. These are lifelines. Vital services that help children survive and thrive. When families can't afford formula, when clinics lose funding for immunization programs, when children lose health coverage, the consequences are immediate and, in many cases, irreversible. As front-line providers, we witness this every day. We can do better. Our federal budget is a reflection of our national values. It should not balance its books on the backs of our youngest and most vulnerable. I implore Wisconsin's elected officials to reject this harmful budget proposal. Think of that infant in the emergency room. Think of the thousands of other children across our state whose health and future depend on robust public health infrastructure, access to care, and support for families in need. We urge lawmakers to work toward a bipartisan budget that invests in children, strengthens public health, and protects the building blocks of a healthy society. Wisconsin's children deserve every opportunity to grow up healthy and strong. Our chapter of the National Association of Pediatric Nurse Practitioners stands ready to partner in this effort. Let's move forward — not backward — when it comes to the health of our children. Christine Schindler is a critical care pediatric nurse practitioner at Children's WI, a clinical professor at Marquette University, and the President of the Wisconsin Chapter of Pediatric Nurse Practitioners. She has been caring for critically ill and injured children for almost 30 years. All opinions expressed are her own. This article originally appeared on Milwaukee Journal Sentinel: Trump budget jeopardizes health of American children | Opinion
Yahoo
an hour ago
- Yahoo
Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30?
Rocket Lab is gaining a reputation for reliability in the rocket launch and space systems market. The company is building on its capabilities and improving its relationships as a defense contractor. While this young sector shows a lot of great promise, the stock looks overvalued today. 10 stocks we like better than Rocket Lab › Space is the final frontier, and it is now turning into a burgeoning economy. Researchers estimate that the space economy is worth over $500 billion with heavy spending from governments around the world along with private-company partners, and that figure is expected to grow to around $1.8 trillion a year by 2035. This is a huge opportunity for start-ups, perhaps rivaled only by artificial intelligence (AI) over the next decade when it comes to both growth rates and size. One company that dominates (and actually built) the entire space market is SpaceX. It's privately held, but luckily, investors have other space economy stocks that are turning into promising businesses. Enter Rocket Lab (NASDAQ: RKLB), the space flight company increasingly competing with SpaceX and developing promising capabilities to grow its presence in this large market. The stock has begun to soar again and is trading at around $26 as of this writing. Should you buy while shares are still under $30? Rocket Lab began its journey in the space economy with its small Electron rocket. It has now begun to expand and vertically integrate various space economy segments. It just acquired a company called Geost for $275 million. Geost develops optical and infrared capabilities for satellites with a focus on selling to the U.S. government's national security satellites. Rocket Lab is used by the government to launch its payloads into space. Now, it will be helping to build and operate these payloads for customers. It keeps vertically integrating its launch and space systems, which gives it a competitive advantage over other companies that only offer one or the other (SpaceX is the only other vertically integrated player). Rocket Lab offers solar energy, radio systems, and software for companies sending missions operating in space. This is why its backlog was over $1 billion as of the end of last quarter. Electron launch missions will continue throughout 2025, hopefully building on the company's strong safety and reliability record. The next step for the company will be testing and launching its larger Neutron rocket for customers. Testing is underway for this rocket right now with a planned mission for a confidential customer sometime in 2026. Larger rockets mean larger payloads, which means more revenue per launch. It also will give the company more of an opportunity to sell its space systems on these launches. The Neutron is the key for Rocket Lab to take the next step in its capabilities as a space flight company and to grow its backlog and revenue. Defense contracts have been a huge part of Rocket Lab's business. It currently helps with Air Force missions and a hypersonic testing program called HASTE. It was recently added to the National Security Space Launch (NSSL) program for its Neutron rocket, another reason why this new rocket is so important for the company's future. A growing relationship with the U.S. government could not have come at a better time for Rocket Lab. The government is set on spending a ton of money on space solutions as the next frontier in national defense. For example, the proposed Golden Dome missile defense project for the U.S. would cost an estimated $175 billion over three years to build. The company would be a prime candidate to win subcontracts for this ambitious project. As the Neutron comes on line and Rocket Lab builds up its capabilities and reputation in the space economy, we should see its backlog climb higher. This is a key indicator for investors to watch. The current backlog will have around half of its revenue recognized over the next 12 months, and half in later periods. In order to grow revenue over the long term, the company will need to grow its backlog and win more contracts from government and commercial customers. There is a lot of potential with Rocket Lab's business, but it might all be priced into the stock (and more) right now. It has a market cap of $12.3 billion. Revenue was only $466 million over the last 12 months. The company has never generated a profit and continues to lose money. If the company is successful with its ambitions to build a vertically integrated space company, it will eventually generate billions of dollars in revenue -- perhaps tens of billions 15 to 20 years from now. However, that is a long way off, and the stock looks fully priced versus what the company can accomplish in the next few years. For this reason, the stock looks like one to avoid even with the price under $30. The business may be promising, but the market is getting ahead of itself with Rocket Lab at the moment. This is a high-risk stock to keep out of your portfolio right now. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab USA. The Motley Fool has a disclosure policy. Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30? was originally published by The Motley Fool